Clinical Trial Update: A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene [Phase 2]

View source ↗

Summary

Phase 2 study evaluating alirocumab in participants with autosomal dominant hypercholesterolemia due to GOFm PCSK9 or LOFm ApoB mutations; study completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Hypercholesterolemia | Phase 2 | Status: COMPLETED | Results posted: 2020-06-17